Now, Hattersley et al. describe the response to sulfonylurea therapy in patients with SUR1 mutations. The study observed 27 patients with SUR1 diabetes after attempted transfer to sulfonylurea ...

The analysis included 41,112 patients starting treatment with GLP-1 RAs; 76,093 starting a dipeptidyl peptidase-4 inhibitor (DPP4i); 43,499 starting a sodium-glucose cotransporter 2 inhibitor (SGLT2i) ...

Overall, a thyroid cancer diagnosis occurred in 0.17% of the GLP-1 agonist group, 0.17% of the SGLT2 inhibitor group, 0.20% of the sulfonylurea group, and 0.23% of the DPP-4 inhibitor group.